Which Six Companies Are in Michael King's Oncology Wheelhouse?
Source: George S. Mack of The Life Sciences Report  (1/10/13)
JMP Securities Managing Director and Senior Biotechnology Analyst Michael King Jr. never recoils from the most sophisticated science. He's always been partial to oncology indications and to new technologies that disrupt old paradigms and usher in the new. King has the kind of stock-picking track record that merits attention, and in this interview with The Life Sciences Report, he brings six important ideas to the table for investors to consider. More >

Five Amazing Biotech Picks with Futuristic Technology
Source: George S. Mack of The Life Sciences Report  (1/10/13)
Michael King is looking for the monoclonal antibodies of tomorrow. When I first spoke to him 15 or more years ago, King was talking up Immunex, which would later be taken out by Amgen Inc. (AMGN:NASDAQ) for $16 billion ($16B) for its antitumor necrosis factor (anti-TNF) fusion protein Enbrel (etanercept) to treat rheumatoid arthritis. Today Amgen's (via Immunex) Enbrel and the anti-TNF monoclonal antibodies that would follow—Johnson & Johnson's (JNJ:NYSE) Remicade (infliximab) and Abbott Laboratories' (ABT:NYSE) Humira (adalimumab)—are blockbusters that could approach $20 billion in sales in 2012. More >

A Low-Risk Potential Double in Biotech
Source: Frank Curzio, Phase 1 Investor  (1/9/13)
"We could see at least 100% returns on this stock within 12–18 months. As we'll show you, based on our research, this forecast could prove extremely conservative." More >

Watchlist 2013: Experts Pick Potential Biotech Winners
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (1/9/13)
More than 75 people packed a conference room at the Biotech Showcase in San Francisco to hear which biotech companies made The Life Sciences Report/Sagient Research Watchlist for 2013. Six experts offered observations on the state of the life sciences sector and each named companies that could prove profitable in the coming year—companies that are not only backed by strong science but are, in the words of Analyst George Zavoico, "poised to be lucky." More >

The Pulse: Breaking News from the Life Sciences Sector
Source: Editors of The Life Sciences Report  (1/7/13)
To invest wisely in the life sciences, broad-spectrum knowledge is key. Such knowledge encompasses not only the analysis of industry experts featured in Streetwise Reports interviews, but also up-to-date news on cutting-edge research and development, the latest mergers and acquisitions and the drug development process, both within companies and in the regulatory arena. Our Twitter feed links you to the information you need to profit, both intellectually and financially. More >

Josh Levine Names Three Biotech Game-Changers
Source: George S. Mack of The Life Sciences Report  (1/3/13)
Micro-cap biotechs must have creative, adaptive management first and foremost, says editor Josh Levine of Josh Levine's MicroCap Investor. A second key characteristic is a technology platform that can ultimately generate a suite of products. In this interview with The Life Sciences Report, Levine shares both his investment philosophy and his best three biotech ideas, all of which he expects will return huge multiples to investors. More >

2012: A Healthy Year for the Life Sciences
Source: Editors of The Life Sciences Report  (12/27/12)
What is the value of innovation? Of addressing unmet needs? Of new and "disruptive" technologies? Those are just a few of the issues that industry experts tackled in interviews with The Life Sciences Report during 2012. Among the many therapeutic focuses discussed by analysts over the last year, orphan diseases and hepatitis C were identified early on as market "sweet spots." Oncology was another big hitter: From micro caps to big pharma, companies targeted the "emperor of all maladies" with innovative pharmaceuticals and genetic technologies. And analysts also uncovered the unexpected, including a pharmaceuticalized nutraceutical designed to reduce high cholesterol. More >

Four Biotech Names with Major Market Potential: Michael Higgins
Source: George S. Mack of The Life Sciences Report   (12/20/12)
A bit of luck and a lot of capital: Drug companies need both to navigate the seemingly perpetual path leading to the market debut of a new drug. Brinson Patrick Securities Managing Director Michael Higgins uses his experience as a drug marketer with big pharma to identify investment opportunities in companies with new drugs that address unmet needs. Higgins serves up his very best ideas to The Life Sciences Report and explains in detail why four growth stocks can rack up huge gains for investors gutsy enough to bet on smaller companies. More >

Crossing the Valley of Death
Source: Alex Philippidis, Genetic Engineering and Biotechnology News  (12/20/12)
BioMotiv says investments in drugs and technologies, not companies, will bring treatments to market faster. More >

Amgen Pleads Guilty, Offers $762M
Source: Genetic Engineering and Biotechnology News  (12/19/12)
"With the Amgen plea deal accepted, the U.S. Department of Justice will have collected more than $14.5B from biopharma companies and others accused of mismarketing their prescription drugs." More >

Top 20 Venture Capital Firms
Source: Genetic Engineering and Biotechnology News  (12/18/12)
"Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies?" More >

Zacks Analyst Jason Napodano's Six Biotech Picks Will Keep Your Profits on Solid Ground
Source: George S. Mack of The Life Sciences Report   (12/13/12)
Low valuation in biotech can be like quicksand under a mirage of low-hanging fruit. That's because the market is inhabited by growth investors who think cheap stocks are cheap for a reason. Zacks Investment Research Senior Biotechnology Analyst Jason Napodano operates with this in mind as he evaluates biotech companies. He also understands that while value can be a good friend, an investor's best buddy is momentum powered by vital market-moving events. Napodano shares his best stock ideas in this Life Sciences Report interview. More >

Do You Have the Guts to Take On Cutting-Edge Biotech Like This VC?
Source: George S. Mack of The Life Sciences Report  (12/13/12)
With the odds stacked against a drug entering clinical trials, investors need to be assured that the upside will be momentous when success does come. Burrill & Co. Managing Director Elemer Piros leverages science and the unmet needs of patients with his extensive knowledge of the capital markets to bring lower-risk, higher-return ideas to investors. In this interview with The Life Sciences Report, Piros explains his investment thesis and zeroes in on best bets. More >

The Next Profit Breakthrough: Synthetic Biology
Source: Michael Robinson, Money Morning  (12/13/12)
"Teams all over the world are now in their labs looking to create novel biotech compounds or drugs by inserting synthetic DNA into cells, either living or artificial." More >

You Say You Want a Revolution. . .
Source: Patrick Cox, The Daily Reckoning  (12/13/12)
"As investors, we have a huge opportunity to invest in early-stage, revolutionary companies working on plant- and animal-based health solutions that bypass the lengthy and extremely expensive FDA approval process." More >

Two Biotech Names Without the Microcap Roller Coaster
Source: George S. Mack of The Life Sciences Report  (12/13/12)
Investors familiar with Zacks Investment Research know that the company is small-cap focused and that it leans heavily toward companies that don't get much coverage from Wall Street. The idea is to produce the kind of sophisticated research you might find in the more recognizable names that get aired on financial television and other media. Battered and forgotten names can be interesting for investors willing to take another look, and biotech can be a particularly rich field for investors looking for turnaround ideas. In fact, this is where Zacks Senior Biotechnology Analyst Jason Napodano is at home. He's not afraid to go all-in with ideas that are anathema to the Street. More >

Cliff Spells Danger for Biotechs
Source: Alex Philippidis, Genetic Engineering and Biotechnology News  (12/12/12)
"If Obama and Congress cannot agree, key agencies face cuts while tax changes would dampen new investment." More >

Top 14 Abused Prescription Drugs
Source: Genetic Engineering and Biotechnology News  (12/11/12)
"Celebrities ranging from Michael Jackson to Rush Limbaugh and from Heath Ledger to Elvis Presley have battled (and, in many cases, lost the battle with) prescription drug addiction. So, which prescription drugs are the biggest culprits?" More >

Breaking Down a Biotech Winner
Source: Alex Daley, Casey Research  (12/11/12)
"The cancer research arena has been exploding over the past few years with the goal of developing more targeted, less-toxic therapies—in other words, to do a better job killing cancer cells while leaving healthy cells alone. More >

Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy
Source: George S. Mack of The Life Sciences Report   (12/6/12)
Many components go into building a successful biotech company, but excellent management is a keystone. Combine good management with an innovative product or service, and investors can possibly unlock big multiples over their original investments. So says Principal Analyst and Fund Manager Ross Silver, co-founder of Vista Partners. In this interview with The Life Sciences Report, Silver brings obscure micro-cap ideas to life and discusses why they may have mammoth potential. More >

Drug Companies Exert Greater Influence on Development
Source: Patricia Dimond, Genetic Engineering and Biotechnology News  (12/6/12)
"In the face of the extraordinary time and cost pressures, companies are making changes to improve R&D efficiency, addressing those factors within their control, such as dumping drug candidates that clearly don't have a chance of making it." More >

Letting Biotech Companies 'Patent Nature' Could Be a Huge Boon for Investors
Source: Michael A. Robinson, Money Morning  (12/6/12)
"Clearly the courts have a vested interest in making sure that American firms continue to get the protections they need to justify spending so much time, money and effort to design new products. On the other hand, the plaintiffs raise a point in this case that cuts to the heart of biotech research—can a company really lay claim to a gene?" More >

Open Innovation in the Pharma Industry
Source: Sue Pearson, Genetic Engineering and Biotechnology News  (12/5/12)
"As many big pharmas are maturing they have become more akin to manufacturing organizations with less internal innovation. This is where accessing science from academic centers of excellence and SMEs can help, and delegates at the conference believe many pharmas are now altering their business model and will increasingly access innovation in drug discovery from external sources." More >

Biotechs Urged to Weigh in as Supreme Court Considers Myriad
Source: Marie Powers, BioWorld  (12/4/12)
"A high court that is decidedly unfriendly toward patent rights also could be leaning toward arguments by the American Civil Liberties Union, on behalf of the Association for Molecular Pathology, and amicus briefs filed by numerous citizens groups contending that patenting gene technology will halt the movement toward personalized medicine." More >

Supreme Court Will Decide Whether Human Genes Are Patentable
Source: Bloomberg, Greg Stohr and Susan Decker  (11/30/12)
"Biotechnology companies say they have been getting patents on genes for 30 years and can't attract investment dollars unless they can protect their research from competitors. The central legal question is whether isolated DNA is a product of nature and thus ineligible for patent protection." More >